However, on the basis of removing amyloid plaques, the US FDA recently gave accelerated approval of aducanumab,  thus further enabling combination treatments to include a treatment to remove amyloid plaques. A combination therapy for AD might address different points in the pathway leading to deposits of aggregated Aβ-42, such as a monoclonal antibody directed toward Aβ-42 and a β-secretase (β-site APP cleaving enzyme 1, or BACE) inhibitor to both remove deposited amyloid via the antibody and reduce the generation of new amyloidogenic isoforms with the BACE inhibitor. Here, BACE1 is linked to Alzheimer disease.